FLYSYN by VERAXA Biotech for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

FLYSYN is under clinical development by VERAXA Biotech and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).

Fetal tissue research gains in importance as roadblocks multiply

Scientists at the University of Wisconsin-Madison have spent years trying to unravel the details of Down syndrome: What happens inside the womb, how the genetic

March 20, 2024

Even Less Aspirin With Ticagrelor-Based DAPT Safe After Stenting for ACS

SAN FRANCISCO — For ticagrelor-based antithrombotic regimens after drug-eluting stent implantation for acute coronary syndrome (ACS), stopping aspirin within the first month appeared to be

October 27, 2023

BIO’s new CEO takes a patriotic pivot to win back Congress, pushing industry to rethink China relationship

SAN DIEGO — Facing an existential moment in how drugs are developed and sold, biotech’s key lobbying group has entrusted a new leader, who is

June 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.